Search

Your search keyword '"Bourreille, A"' showing total 1,144 results

Search Constraints

Start Over You searched for: Author "Bourreille, A" Remove constraint Author: "Bourreille, A"
1,144 results on '"Bourreille, A"'

Search Results

1. Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID

2. Role of ICAM-1 in the Adhesion of T Cells to Enteric Glia: Perspectives in the Formation of Plexitis in Crohn’s DiseaseSummary

5. Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID

6. Adalimumab in Biologic-naïve Patients With Crohn’s Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID

7. Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study

8. Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe dʼEtude Thérapeutique des Affections Inflammatoires du Tube Digestif

9. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

10. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

11. The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics

12. Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID

13. Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID

14. Transfusion-Related Renal Dysfunction After Cardiac Surgery: The Role of Myeloid-Related Protein_14 in Neutrophil-Mediated Tubular Damage

15. La vidéo-capsule gastrique à commande magnétique guidée par intelligence artificielle : la fin de la gastroscopie conventionnelle ?

17. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

18. Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine

19. Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group

20. Key research questions for implementation of artificial intelligence in capsule endoscopy

21. IL-22BP production is heterogeneously distributed in Crohn’s disease

23. Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study

24. Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study

25. Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trial

26. Protocol of a multicentric prospective cohort study for the VALIDation of the IBD-disk instrument for assessing disability in inflammatory bowel diseases: the VALIDate study

30. Role of ICAM-1 in the Adhesion of T Cells to Enteric Glia: Perspectives in the Formation of Plexitis in Crohn’s Disease

32. P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID

33. P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial

34. P903 Persistence, efficacy and tolerance of subcutaneous Infliximab after switch from intravenous infliximab in IBD patients in remission: one-year results from a multicenter prospective cohort

35. DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort

37. Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID.

38. Multi-expert annotation of Crohn’s disease images of the small bowel for automatic detection using a convolutional recurrent attention neural network

39. Expression of CCR6 and CXCR6 by Gut-Derived CD4+/CD8α+ T-Regulatory Cells, Which Are Decreased in Blood Samples From Patients With Inflammatory Bowel Diseases

40. High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease

41. An intermediate level of CD161 expression defines a novel activated, inflammatory, and pathogenic subset of CD8+ T cells involved in multiple sclerosis

42. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease

44. Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn’s Disease in Sustained Remission

45. Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases

46. The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics

47. Prevalence of and factors associated with extraintestinal manifestations and their remission in inflammatory bowel disease: the EXTRA prospective study from the GETAID

48. Myeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative Colitis

49. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

50. Neuropathologic, phenotypic and functional analyses of Mucosal Associated Invariant T cells in Multiple Sclerosis

Catalog

Books, media, physical & digital resources